Increasing integrated testing in community settings through interventions for change, including the Spring European Testing Week.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
13 Sep 2021
Historique:
received: 03 08 2021
accepted: 06 08 2021
entrez: 14 9 2021
pubmed: 15 9 2021
medline: 25 9 2021
Statut: epublish

Résumé

Maximising access to testing by targeting more than one infection is effective in identifying new infections in settings or populations. Within the EU funded Joint Action INTEGRATE, this paper examined the feasibility and impact of expanding integrated testing for HIV, hepatitis C (HCV), chlamydia, gonorrhoea and/or syphilis in four community-based pilots through targeted interventions in Croatia, Italy and Poland and the Spring European Testing Week since community settings are key in detecting new infections and reaching key populations. Pilots led by local INTEGRATE partners prioritised testing for other infections or key populations. The Croatian pilot expanded testing for men who have sex with men to syphilis, chlamydia and gonorrhoea. Italian partners implemented a HIV and HCV testing/information event at a migrant centre. A second Italian pilot tested migrants for HIV and HCV through outreach and a low-threshold service for people who use drugs. Polish partners tested for HIV, HCV and syphilis among people who inject drugs in unstable housing via a mobile van. Pilots monitored the number of individuals tested for each infection and reactive results. The pilot Spring European Testing Week from 18 to 25 May 2018 was an INTEGRATE-driven initiative to create more testing awareness and opportunities throughout Europe. The Croatian pilot found a high prevalence for each syphilis, chlamydia and gonorrhoea respectively, 2.1%, 12.4% and 6.7%. The Italian migrant centre pilot found low proportions who were previously tested for HIV (24%) or HCV (11%) and the second Italian pilot found an HCV prevalence of 6.2%, with low proportions previously tested for HIV (33%) or HCV (31%). The Polish pilot found rates of being previously tested for HIV, HCV and syphilis at 39%, 37%, and 38%, respectively. Results from the Spring European Testing Week pilot showed it was acceptable with increased integrated testing, from 50% in 2018 to 71% in 2019 in participants. Results show that integrated testing is feasible and effective in community settings, in reaching key populations and minimising missed testing opportunities, and the pilots made feasible because of the European collaboration and funding. For sustainability and expansion of integrated community testing across Europe, local government investment in legislation, financial and structural support are crucial.

Sections du résumé

BACKGROUND BACKGROUND
Maximising access to testing by targeting more than one infection is effective in identifying new infections in settings or populations. Within the EU funded Joint Action INTEGRATE, this paper examined the feasibility and impact of expanding integrated testing for HIV, hepatitis C (HCV), chlamydia, gonorrhoea and/or syphilis in four community-based pilots through targeted interventions in Croatia, Italy and Poland and the Spring European Testing Week since community settings are key in detecting new infections and reaching key populations.
METHODS METHODS
Pilots led by local INTEGRATE partners prioritised testing for other infections or key populations. The Croatian pilot expanded testing for men who have sex with men to syphilis, chlamydia and gonorrhoea. Italian partners implemented a HIV and HCV testing/information event at a migrant centre. A second Italian pilot tested migrants for HIV and HCV through outreach and a low-threshold service for people who use drugs. Polish partners tested for HIV, HCV and syphilis among people who inject drugs in unstable housing via a mobile van. Pilots monitored the number of individuals tested for each infection and reactive results. The pilot Spring European Testing Week from 18 to 25 May 2018 was an INTEGRATE-driven initiative to create more testing awareness and opportunities throughout Europe.
RESULTS RESULTS
The Croatian pilot found a high prevalence for each syphilis, chlamydia and gonorrhoea respectively, 2.1%, 12.4% and 6.7%. The Italian migrant centre pilot found low proportions who were previously tested for HIV (24%) or HCV (11%) and the second Italian pilot found an HCV prevalence of 6.2%, with low proportions previously tested for HIV (33%) or HCV (31%). The Polish pilot found rates of being previously tested for HIV, HCV and syphilis at 39%, 37%, and 38%, respectively. Results from the Spring European Testing Week pilot showed it was acceptable with increased integrated testing, from 50% in 2018 to 71% in 2019 in participants.
CONCLUSIONS CONCLUSIONS
Results show that integrated testing is feasible and effective in community settings, in reaching key populations and minimising missed testing opportunities, and the pilots made feasible because of the European collaboration and funding. For sustainability and expansion of integrated community testing across Europe, local government investment in legislation, financial and structural support are crucial.

Identifiants

pubmed: 34517819
doi: 10.1186/s12879-021-06555-0
pii: 10.1186/s12879-021-06555-0
pmc: PMC8438814
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

874

Subventions

Organisme : Third Health Programme of the European Union
ID : 761319
Organisme : Gilead Sciences
ID : 03976
Organisme : Fundação para a Ciência e Tecnologia (FCT)
ID : PD/BD/128008/2016

Informations de copyright

© 2021. The Author(s).

Références

PLoS One. 2014 Apr 04;9(4):e93734
pubmed: 24705595
AIDS Behav. 2019 Sep;23(9):2273-2303
pubmed: 31006047
J Int AIDS Soc. 2014 Nov 02;17(4 Suppl 3):19598
pubmed: 25394102
Int J STD AIDS. 2017 May;28(6):573-583
pubmed: 26945592
J Acquir Immune Defic Syndr. 2017 Jul 1;75(3):315-321
pubmed: 28418991
BMC Public Health. 2013 Aug 08;13:737
pubmed: 23923977
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21658
pubmed: 28770592
BMC Res Notes. 2017 Jan 4;10(1):20
pubmed: 28057054
Lancet Infect Dis. 2020 Feb;20(2):e47-e53
pubmed: 31740252
AIDS Care. 2017 Dec;29(12):1473-1479
pubmed: 28436276
BMC Public Health. 2018 Jun 18;18(1):748
pubmed: 29914449
BMC Public Health. 2020 Jun 30;20(1):1039
pubmed: 32605605
Sex Transm Infect. 2015 Jun;91(4):294-9
pubmed: 25504922
JMIR Public Health Surveill. 2017 Nov 06;3(4):e84
pubmed: 29109072
AIDS Behav. 2015 Nov;19(11):2012-24
pubmed: 26025193
HIV Med. 2015 Feb;16(2):88-94
pubmed: 25123958
AIDS Care. 2015;27(6):767-71
pubmed: 25566879
AIDS Rev. 2016 Jan-Mar;18(1):3-14
pubmed: 26991825
Dig Liver Dis. 2019 Jul;51(7):915-921
pubmed: 31031174

Auteurs

Nadia Gasbarrini (N)

Fondazione Villa Maraini, Rome, Italy.

Davor Dubravić (D)

Croatian Association for HIV and Viral Hepatitis (HUHIV), Zagreb, Croatia.

Lauren Combs (L)

CHIP, Centre of Excellence for Health, Immunity and Infections,, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100, Copenhagen Ø, Denmark.

Arian Dišković (A)

Croatian Association for HIV and Viral Hepatitis (HUHIV), Zagreb, Croatia.

Magdalena Ankiersztejn-Bartczak (M)

Foundation for Social Education, Warsaw, Poland.

Francesca Colaiaco (F)

Associazione Della Croce Rossa Italiana (CRI), Rome, Italy.

Iwona Wawer (I)

National AIDS Centre, Agency of the Ministry of Health, Warsaw, Poland.

Piotr Wysocki (P)

National AIDS Centre, Agency of the Ministry of Health, Warsaw, Poland.

Magdalena Rosińska (M)

Department of Epidemiology of Infectious Diseases and Surveillance, National Institute of Public Health - National Institute of Hygiene, Warsaw, Poland.

Anna Marzec-Boguslawska (A)

National AIDS Centre, Agency of the Ministry of Health, Warsaw, Poland.

Ben Collins (B)

ReShape/International HIV Partnerships, London, UK.

Daniel Simões (D)

EPIUnit - Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal.

Marie Louise Jakobsen (ML)

CHIP, Centre of Excellence for Health, Immunity and Infections,, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100, Copenhagen Ø, Denmark.

Dorthe Raben (D)

CHIP, Centre of Excellence for Health, Immunity and Infections,, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100, Copenhagen Ø, Denmark. dorthe.raben@regionh.dk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH